Barbara Gatto

Summary

Affiliation: University of Padova
Country: Italy

Publications

  1. ncbi 2-Phenylquinolones as inhibitors of the HIV-1 Tat-TAR interaction
    Barbara Gatto
    Dipartimento di Scienze Farmaceutiche, Universita di Padova, Via Marzolo 5, 35131 Padova, Italy
    ChemMedChem 4:935-8. 2009
  2. ncbi Nucleic acid aptamers based on the G-quadruplex structure: therapeutic and diagnostic potential
    B Gatto
    University of Padova, Department of Pharmaceutical Sciences, Via Marzolo, 5 35131 Padova, Italy
    Curr Med Chem 16:1248-65. 2009
  3. ncbi Monoclonal antibodies in cancer therapy
    Barbara Gatto
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova
    Curr Med Chem Anticancer Agents 4:411-4. 2004
  4. ncbi From proteins to nucleic acid-based drugs: the role of biotech in anti-VEGF therapy
    Barbara Gatto
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
    Anticancer Agents Med Chem 6:287-301. 2006
  5. ncbi The topoisomerase II poison clerocidin alkylates non-paired guanines of DNA: implications for irreversible stimulation of DNA cleavage
    B Gatto
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
    Nucleic Acids Res 29:4224-30. 2001
  6. ncbi Biologics targeted at TNF: design, production and challenges
    B Gatto
    Department of Pharmaceutical Sciences, University of Padova
    Reumatismo 58:94-103. 2006
  7. ncbi Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells
    Barbara Gatto
    University of Padova, Department of Pharmaceutical Sciences, Padova, Italy
    Curr Opin Investig Drugs 9:1216-27. 2008
  8. ncbi Drugs acting on the beta isoform of human topoisomerase II (p180)
    B Gatto
    Dept of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
    Curr Med Chem Anticancer Agents 3:173-85. 2003
  9. ncbi Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative
    Sara Richter
    Department of Pharmaceutical Sciences, University of Padua, 35131 Padua, Italy
    Antimicrob Agents Chemother 48:1895-9. 2004
  10. ncbi Clerocidin interacts with the cleavage complex of Streptococcus pneumoniae topoisomerase IV to induce selective irreversible DNA damage
    Sara N Richter
    Department of Pharmaceutical Sciences, University of Padova, 35131 Padova, Italy
    Nucleic Acids Res 34:1982-91. 2006

Collaborators

Detail Information

Publications29

  1. ncbi 2-Phenylquinolones as inhibitors of the HIV-1 Tat-TAR interaction
    Barbara Gatto
    Dipartimento di Scienze Farmaceutiche, Universita di Padova, Via Marzolo 5, 35131 Padova, Italy
    ChemMedChem 4:935-8. 2009
    ....
  2. ncbi Nucleic acid aptamers based on the G-quadruplex structure: therapeutic and diagnostic potential
    B Gatto
    University of Padova, Department of Pharmaceutical Sciences, Via Marzolo, 5 35131 Padova, Italy
    Curr Med Chem 16:1248-65. 2009
    ....
  3. ncbi Monoclonal antibodies in cancer therapy
    Barbara Gatto
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova
    Curr Med Chem Anticancer Agents 4:411-4. 2004
    ..Moreover, a thorough understanding of the cellular and molecular events underlying the activity of cancer-aimed antibodies allows the optimisation of these drugs for the treatment of high incidence solid tumors...
  4. ncbi From proteins to nucleic acid-based drugs: the role of biotech in anti-VEGF therapy
    Barbara Gatto
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
    Anticancer Agents Med Chem 6:287-301. 2006
    ..Their design, production and clinical advancement in cancer and other pathological conditions linked to angiogenesis will be specifically addressed in this review...
  5. ncbi The topoisomerase II poison clerocidin alkylates non-paired guanines of DNA: implications for irreversible stimulation of DNA cleavage
    B Gatto
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
    Nucleic Acids Res 29:4224-30. 2001
    ....
  6. ncbi Biologics targeted at TNF: design, production and challenges
    B Gatto
    Department of Pharmaceutical Sciences, University of Padova
    Reumatismo 58:94-103. 2006
    ....
  7. ncbi Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells
    Barbara Gatto
    University of Padova, Department of Pharmaceutical Sciences, Padova, Italy
    Curr Opin Investig Drugs 9:1216-27. 2008
    ..Atacicept is undergoing phase II/III clinical trials for systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, as well as for several B-cell malignancies...
  8. ncbi Drugs acting on the beta isoform of human topoisomerase II (p180)
    B Gatto
    Dept of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
    Curr Med Chem Anticancer Agents 3:173-85. 2003
    ....
  9. ncbi Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative
    Sara Richter
    Department of Pharmaceutical Sciences, University of Padua, 35131 Padua, Italy
    Antimicrob Agents Chemother 48:1895-9. 2004
    ..Furthermore, WM5 disrupts the natural protein-nucleic acid complex with a 50% inhibitory concentration in the low micromolar range in both in vitro and in vivo assays...
  10. ncbi Clerocidin interacts with the cleavage complex of Streptococcus pneumoniae topoisomerase IV to induce selective irreversible DNA damage
    Sara N Richter
    Department of Pharmaceutical Sciences, University of Padova, 35131 Padova, Italy
    Nucleic Acids Res 34:1982-91. 2006
    ..The unique ability to form exclusively irreversible DNA breaks suggests topoisomerase IV may be a key intracellular target of CL in bacteria...
  11. ncbi Clerocidin alkylates DNA through its epoxide function: evidence for a fine tuned mechanism of action
    Sara Richter
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
    Nucleic Acids Res 31:5149-56. 2003
    ..Its oxidation state seems crucial to modulate the rates of reactivity by finely tuning the strain applied on the oxirane ring...
  12. ncbi Antiviral 6-amino-quinolones: molecular basis for potency and selectivity
    Sara N Richter
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
    Bioorg Med Chem Lett 15:4247-51. 2005
    ..Interestingly, the basicity of the above substituent modulates chelation of the quinolone template to magnesium ions, which, in turn, critically affects the potency and target selectivity in the antiviral quinolone family...
  13. ncbi Involvement of p53 in specific anti-neuroectodermal tumor activity of aloe-emodin
    Teresa Pecere
    Department of Histology, Microbiology and Medical Biotechnology, University of Padova, Padua, Italy
    Int J Cancer 106:836-47. 2003
    ..Due to its high accumulation in neuroectodermal tumor cells AE could also kill tumor cells harboring p53 mutant genes. This property would further contribute to AE specific anti-tumor activity and might be exploitable in the clinic...
  14. ncbi Sequence-specific interactions of drugs interfering with the topoisomerase-DNA cleavage complex
    Manlio Palumbo
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padua, Italy
    Biochim Biophys Acta 1587:145-54. 2002
    ....
  15. ncbi Rational design, synthesis, and DNA binding properties of novel sequence-selective peptidyl congeners of ametantrone
    Alessandra Gianoncelli
    Dipartimento di Scienze Farmaceutiche, Universita di Padova, Via Marzolo 5, 35131 Padova, Italy
    ChemMedChem 5:1080-91. 2010
    ....
  16. ncbi Effects of common buffer systems on drug activity: the case of clerocidin
    Sara Richter
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
    Chem Res Toxicol 17:492-501. 2004
    ....
  17. ncbi Perylene side chains modulate G-quadruplex conformation in biologically relevant DNA sequences
    Claudia Pivetta
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo, 5 35131 Padova, Italy
    Bioorg Med Chem 16:9331-9. 2008
    ....
  18. ncbi The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein
    Arianna Loregian
    Department of Histology, Microbiology and Medical Biotechnologies, University of Padua, Padua, Italy
    Antimicrob Agents Chemother 54:1930-40. 2010
    ..Finally, WC5 combined with ganciclovir in checkerboard experiments exhibited highly synergistic activity. These findings suggest that WC5 deserves further investigation as a candidate anti-HCMV drug with a novel mechanism of action...
  19. ncbi Anthracyclines: recent developments in their separation and quantitation
    G Zagotto
    Department of Pharmaceutical Sciences, University of Padova, Italy
    J Chromatogr B Biomed Sci Appl 764:161-71. 2001
    ..This review describes the most recent developments in the separation and quantitation of the above clinically useful drugs, together with their principal metabolites. Some less widely used derivatives will also be considered...
  20. ncbi Quantitation of camptothecin and related compounds
    M Palumbo
    Department of Pharmaceutical Sciences, University of Padova, Italy
    J Chromatogr B Biomed Sci Appl 764:121-40. 2001
    ..Hence, the conditions of extraction, pre-treatment and quantitative analysis are to be carefully calibrated in order to provide meaningful results...
  21. ncbi The evolving world of protein-G-quadruplex recognition: a medicinal chemist's perspective
    Claudia Sissi
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, Padua, Italy
    Biochimie 93:1219-30. 2011
    ..In this review we examine protein-G-quadruplex recognition in physiologically significant conditions and discuss how to possibly exploit the interactions' selectivity for targeted therapeutic intervention...
  22. ncbi Novel pyrrolo[3,2-f]quinolines: synthesis and antiproliferative activity
    M G Ferlin
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
    Bioorg Med Chem 9:1843-8. 2001
    ..Comparison with previously investigated regioisomers shows modulation of activity dictated by the position and conformational freedom of side-chain groups...
  23. ncbi Ellagic acid and polyhydroxylated urolithins are potent catalytic inhibitors of human topoisomerase II: an in vitro study
    Valentina Furlanetto
    Dipartimento di Scienze del Farmaco, Universita di Padova, Via Marzolo 5, 35131 Padova, Italy
    J Agric Food Chem 60:9162-70. 2012
    ..Docking experiments show that the active compounds bind the ATP pocket of the human enzyme, thus supporting the hypothesis that EA and polyhydroxylated urolithins act as ATP-competitive inhibitors of human topoisomerase II...
  24. ncbi Human thrombin detection through a sandwich aptamer microarray: interaction analysis in solution and in solid phase
    Alice Sosic
    Dipartimento di Scienze Farmaceutiche, University of Padova, Via F Marzolo 5, I 35131 Padova, Italy
    Sensors (Basel) 11:9426-41. 2011
    ..Finally, the best procedure for Sandwich Aptamer Microarray (SAM) and the specificity of the sandwich formation for the developed aptasensor for human thrombin were optimized...
  25. ncbi Effective DNA inhibitors of cathepsin g by in vitro selection
    Barbara Gatto
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
    Int J Mol Sci 9:1008-23. 2008
    ..This unprecedented finding is validated by our results showing high affinity and inhibition of CatG by specific DNA sequences of variable length designed to maximally reduce pairing/folding interactions...
  26. ncbi In vitro selection of DNA aptamers that bind L-tyrosinamide
    E Vianini
    Department of Pharmaceutical Sciences, University of Padova, via 5, 35131 Padova, Marzolo, Italy
    Bioorg Med Chem 9:2543-8. 2001
    ..The identified aptamer sequence will constitute the basis for further in vitro evolution protocols and structure-based drug design...
  27. ncbi Design, synthesis, and biological properties of new bis(acridine-4-carboxamides) as anticancer agents
    Ippolito Antonini
    Department of Chemical Sciences, University of Camerino, Via S Agostino 1, 62032 Camerino, Italy
    J Med Chem 46:3109-15. 2003
    ..Some highly DNA-affinic and potent cytotoxic compounds, 9b,f and 13b,c, have been selected for the National Cancer Institute (NCI) screening on 60 human tumor cell lines and identified as new leads in the antitumor strategies...
  28. ncbi 2,6-Di(omega-aminoalkyl)-2,5,6,7-tetrahydropyrazolo[3,4,5-mn]pyrimido[5,6,1-de]acridine-5,7-diones: novel, potent, cytotoxic, and DNA-binding agents
    Ippolito Antonini
    Department of Chemical Sciences, University of Camerino, Via S Agostino 1, 62032 Camerino, Italy
    J Med Chem 45:696-702. 2002
    ..The 2,6-di(omega-aminoalkyl)-2,5,6,7-tetrahydropyrazolo[3,4,5-mn]pyrimido[5,6,1-de]acridine-5,7-diones (4) constitute a new class of potent, cytotoxic DNA-binding agents not cross-resistant with doxorubicin...
  29. ncbi New anti-human immunodeficiency virus type 1 6-aminoquinolones: mechanism of action
    Cristina Parolin
    Department of Histology, Microbiology and Medical Biotechnologies, Section of Microbiology and Virology, University of Padua, Italy
    Antimicrob Agents Chemother 47:889-96. 2003
    ..6 nM). These data indicate that WM5 is a promising lead compound for the development of a new class of HIV-1 transcription inhibitors characterized by recognition of viral RNA target(s)...